Ultrasound-Guided Erector Spinae Plane Block Versus Oblique Subcostal Transversus Abdominis Plane Block in Laparoscopic Cholecystectomy

NCT ID: NCT06640062

Last Updated: 2024-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-01

Study Completion Date

2024-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this work was to compare the effect of using oblique subcostal transversus abdominis plane (OSTAP) block and erector spinae plane (ESP) block as a part of multi-modal analgesia technique in patients undergoing laparoscopic cholecystectomy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Laparoscopic cholecystectomy is a commonly performed surgery and requires multi-modal analgesia for better control of pain. Untreated post-operative pain has many consequences, including patient dissatisfaction, transition into chronic pain, delayed discharge from the hospital, and increased healthcare costs.

Many inter-fascial plane blocks like oblique subcostal transversus abdominis plane (OSTAP) block and recently, erector spinae plane (ESP) block have been utilized as a part of multi modal analgesia technique in many abdominal surgeries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ultrasound Erector Spinae Plane Block Oblique Subcostal Transversus Abdominis Plane Block Laparoscopic Cholecystectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Erector spinae plane block group

Patients received ultrasound-guided erector spinae plane block.

Group Type ACTIVE_COMPARATOR

Erector spinae plane block

Intervention Type OTHER

Patients received ultrasound-guided erector spinae plane block.

Oblique subcostal transversus abdominis plane block group

Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.

Group Type EXPERIMENTAL

Oblique subcostal transversus abdominis plane block

Intervention Type OTHER

Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Erector spinae plane block

Patients received ultrasound-guided erector spinae plane block.

Intervention Type OTHER

Oblique subcostal transversus abdominis plane block

Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 20 to 60 years.
* Both gender.
* American Society of Anesthesiologists (ASA) grade I and II physical status.
* Body mass index (BMI): ≥ 20 kg/m2 and ≤ 35 kg/m2.
* Underwent laparoscopic cholecystectomy.

Exclusion Criteria

* Patient refusal.
* Known sensitivity or contraindication to drugs used in the study (local anesthetics, opioids).
* History of psychological disorders and/or chronic pain syndrome.
* Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy.
* Severe respiratory disorders such as (severe obstructive pulmonary disease, forced expiratory volume (FEV1), forced vital capacity (FVC) \<50% or severe restrictive pulmonary disease, and adult respiratory distress syndrome).
* Severe cardiac disorders such as (heart failure).
* Advanced liver disease (elevated liver enzymes more than 3 folds of normal range).
* Advanced kidney disease (Decreased creatinine clearance \<40 ml/min).
* Pregnancy.
Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Helwan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Fayez Yousef Metias

Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Helwan University, Egypt.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Helwan University

Helwan, Cairo Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

118-2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.